Madrigal Pharmaceuticals Appoints Dr. Jacqualyn Fouse
CONSHOHOCKEN, Pa. — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a pioneering biopharmaceutical company, has announced a significant addition to its Board of Directors with the appointment of Dr. Jacqualyn Fouse. This move comes as the company continues to innovate in the treatment options available for metabolic dysfunction-associated steatohepatitis (MASH).
Farewell to Fred Craves, Ph.D.
As part of this transition, Fred Craves, Ph.D., has indicated his intention to retire from the Board of Directors in July 2025. His tenure has been notable for its contributions throughout Madrigal's journey, influencing the company's strategic direction and growth.
Welcoming Dr. Fouse
Julian Baker, Chairman of Madrigal's Board, expressed enthusiasm about Dr. Fouse's onboarding, highlighting her extensive experience in the healthcare and finance sectors. “Dr. Fouse’s expertise in biotechnology and her robust professional background will make her a valuable asset as we navigate the complexities of our field,” he noted.
A Vision for the Future
Bill Sibold, the Chief Executive Officer of Madrigal, affirmed that Dr. Fouse’s appointment aligns with the company's long-term aspirations for leadership in MASH treatment. With a focus on expanding the reach of Rezdiffra, Madrigal's innovative medication, the company aims to enhance its clinical programs for patients suffering from compensated MASH cirrhosis.
Dr. Fouse’s Impressive Background
Before her new role at Madrigal, Dr. Fouse served as the Chief Executive Officer of Agios Pharmaceuticals, where she played a crucial role in shaping the company’s strategic direction from 2019 to 2022. Her previous endeavors also include pivotal positions at Celgene Corporation, where she held several executive roles, including President and Chief Operating Officer. With degrees in economics and finance, her academic credentials further bolster her qualifications for the role.
Commitment to Patient Care
Dr. Fouse expressed her excitement about joining Madrigal, highlighting the impact the company has made on improving care for patients grappling with MASH. She noted the challenges faced in developing treatments for this condition and praised Madrigal’s innovative approach to launching Rezdiffra.
Madrigal's Role in MASH Treatment
Madrigal Pharmaceuticals is dedicated to addressing the critical unmet needs of patients with MASH. The company’s flagship medication, Rezdiffra (resmetirom), represents a significant advancement, targeting key aspects of the disease's progression. This therapy has been approved by the FDA for patients with moderate to advanced fibrosis, offering hope to many in need.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. is on the forefront of biopharmaceutical development, working tirelessly to create innovative therapeutic solutions for liver diseases like MASH. With Rezdiffra being the first approved agent for the treatment of MASH with advanced fibrosis, the company is positioned to lead in this niche market.
Looking Ahead
The ongoing Phase 3 trial evaluating Rezdiffra for compensated MASH cirrhosis underscores Madrigal's commitment to enhancing patient treatment outcomes and exploring further geographical expansion. With leadership like Dr. Fouse, the company's objectives are more attainable, promising a brighter future for MASH patients.
Frequently Asked Questions
Who is Dr. Jacqualyn Fouse?
Dr. Jacqualyn Fouse is the newly appointed Board member of Madrigal Pharmaceuticals and has extensive experience in the biotech industry.
What is Madrigal Pharmaceuticals known for?
Madrigal Pharmaceuticals specializes in developing innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH).
What does Rezdiffra treat?
Rezdiffra is the first FDA-approved treatment for patients with MASH presenting moderate to advanced fibrosis.
When is Fred Craves retiring?
Fred Craves will retire from Madrigal’s Board in July 2025 after providing exemplary service during his tenure.
What future plans does Madrigal have?
Madrigal aims to expand the geographical reach of its treatments and enhance its clinical programs focusing on MASH.
